Immune response results of vesigenurtacel-l (HS-410) in combination with BCG from a randomized phase II trial in patients with non-muscle invasive bladder cancer (NMIBC). Meeting Abstract

cited authors

  • Steinberg, Gary D.; Shore, Neal D.; Karsh, Lawrence Ivan; Bailen, James L.; Bivalacqua, Trinity J.; Chamie, Karim

Publication Date

  • February 20, 2017

webpage

published in

category

volume

  • 35

issue

  • 6